INTRODUCTION
Percutaneously inserted silicone central venous catheters have been an essential part of the management of neonates for the last two decades.
1,2 Because of fibrin deposition, these catheters can become occluded or, less commonly, adherent to the wall of the vessel in which they reside. 3 -5 Malassezia furfur is a lipophilic fungus that is occasionally found in central venous catheters, particularly if they are used for the infusion of fat emulsions. 6 M. furfur is one of the organisms implicated both in catheter occlusion 7 and in the adhesion of catheters to the vein wall. 3 In addition, it can cause systemic illness. 8, 9 We report two cases in which thrombolytic agents facilitated the removal of silicone central venous catheters that were both occluded and adherent to the vessel wall as a result of infection with M. furfur.
CLINICAL SUMMARY Case 1
A male infant born at 30 weeks' gestation weighing 1490 g was transferred to our intensive care nursery at 4 days of age for treatment of a spontaneous ileal perforation. He underwent resection of the terminal ileum and placement of an ileostomy, and was treated with antibiotics. At 6 days of age, a 2-French silicone catheter (Epicutaneo-Cave-Catheter, Vygon, Germany) was inserted percutaneously through a right antecubital vein to facilitate treatment with parenteral nutrition. On the 22nd day after insertion of the catheter, the patient developed apnea and bradycardia. The initial evaluation revealed a white blood cell count of 6100/mm 3 with 38% segs and 20% bands, and platelet count of 268,000; treatment with Vancomycin and Claforan was initiated. Blood culture was negative for both bacteria and fungus at 72 hours. Two days after the onset of apnea and bradycardia, the catheter was occluded, and a white precipitate was seen in the tubing connecting the catheter to the intravenous fluids. Gram stain of the precipitate showed yeast with the typical morphology of M. furfur. A culture of the fluid from this tubing, which was sent specifically for detection of M. furfur, was subsequently positive. A peripheral intravenous device was placed for administration of parenteral nutrition including intravenous lipids; the triglyceride level was 92 mg/dl during the week that the infection with M. furfur was noted.
The initial attempt to remove the occluded catheter was unsuccessful. Several attempts to remove the catheter using consistent, gentle traction 4 over 3 days were also unsuccessful. An echocardiogram was obtained, and showed a thrombus in the superior vena cava in the region of the silicone catheter. Hypothesizing that lysis of this thrombus would allow the removal of the adherent Silastic catheter, we infused urokinase (Abbokinase, Abbott Laboratories, North Chicago, IL) at 4000 U/kg per hour through a newly placed catheter, which was positioned with the tip in the superior vena cava near the thrombus. Two and a half hours later, the original catheter was removed with gentle traction, and the urokinase infusion was stopped. Complete removal was confirmed by measuring the length of the catheter, and comparing it to the preinsertion length. The catheter tip cultured M. furfur. The day after
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catheter removal, a repeat echocardiogram showed no evidence of any remaining thrombus in the superior vena cava. Immediately before initiating urokinase therapy, a cranial ultrasound revealed a left germinal matrix hemorrhage. One month later, a follow-up cranial ultrasound was normal. The patient was discharged home in stable condition at 3 months of age.
Case 2
A female infant born at 25 weeks' gestation weighing 670 g was transferred to our intensive care nursery on her first day of life. Her course included severe respiratory distress syndrome that progressed to significant chronic lung disease. At 1 day of age, a Silastic catheter was inserted percutaneously into the right saphenous vein at the knee for administration of parenteral nutrition.
On day 28, a white precipitate was noted in the clear connecting tubing of the silicone catheter. Fluid from the tubing was sent for culture, and was positive for M. furfur. An evaluation for sepsis was done, and the white blood cell count was 10.3/mm 3 , with 34% segs and 24% bands, and the platelet count was 45,000. Although the catheter remained patent, the decision was made to remove it and place a new catheter due to the patient's unstable clinical status, limited peripheral veins, and the need for stable vascular access for vasopressor and glucose infusions.
When attempting to remove the catheter, it was found to be firmly stuck. An abdominal ultrasound failed to detect any thrombi in the inferior vena cava where the catheter tip was located. Over the next 3 days multiple attempts were made to remove the catheter using gentle, continuous traction 4 without success. During one attempt the catheter was stretched to the point that it was feared it might break off, and no further attempts to remove the catheter by traction were made. Intravenous lipids were discontinued, and antifungal systemic treatment with Amphotericin B was initiated due to the deteriorating clinical course and inability to remove the infected catheter. Triglyceride levels were 88 mg/dl the week before M. furfur infection, and 118 mg/dl the day after the infection was confirmed.
Despite the failure to find a thrombus on abdominal ultrasound, we believed that fibrin deposition around the catheter was causing adherence of the catheter. We therefore elected to begin a trial of recombinant tissue plasminogen activator (r-TPA, Activase, Genentech, San Francisco, CA) to facilitate removal of the catheter, to be followed by surgical removal if unsuccessful. A single 0.1-mg dose of r-TPA was injected intravenously through the retained catheter, followed by an unsuccessful attempt at removal 1 hour later. Later, a 0.5-cm incision was made by the pediatric surgeon at the level of the knee and, although the catheter was identified and exposed, it could not be removed, suggesting that adherence was further up the vein. Following the unsuccessful surgical intervention, we began a continuous infusion of r-TPA at 0.2 mg/hr through a peripheral IV in the hand. Attempts were made periodically to remove the catheter. After 20 hours the catheter was removed intact. Complete removal was confirmed by measuring the length of the catheter, and comparing it to the preinsertion length. Culture of the catheter tip showed no microorganisms.
During the r-TPA infusion fibrinogen levels were monitored. No clinical bleeding was noted during the infusion of r-TPA. A cranial ultrasound obtained immediately before initiating r-TPA had no evidence of intraventricular hemorrhage. Follow-up cranial ultrasounds were also normal. The patient was discharged home at 4-1/2 months of age.
DISCUSSION
M. furfur colonization has been reported to occur in rates of 36.8% to 64% of infants hospitalized in neonatal intensive care units. 10, 11 Colonization of intravenous catheters is thought to be secondary to skin colonization. It is identified by a typical white ''fluffy'' precipitate, which appears in the clear connecting tubing of the catheter. Although M. furfur has a characteristic appearance on gram stain, it does not grow on routine culture. If M. furfur is suspected, it should be cultured in oil-enriched media.
12 M. furfur infections are not usually associated with severe systemic illness, although some infants may develop symptoms such as bradycardia, fever, increased respiratory distress, or signs of necrotizing enterocolitis. 7 Prompt removal of the line once colonization is identified is the optimal treatment. Systemic antifungal therapy is controversial; some report it is neither effective nor required once the catheter is removed, 9,13,14 whereas others recommend treatment with amphotericin B in patients who remain fungemic with persistent fever or thrombocytopenia after removing the infected catheter and discontinuing intravenous lipids. 6 Retained catheters are a rare complication that has been reported to be associated with infection with both M. furfur and S. epidermidis. 3, 4 The most likely mechanism for catheters adherence is the development of thrombi or fibrin sheaths on the surface of infected catheters, causing the catheter to become adherent to the vein wall. 3, 9, 16 In our experience, adhered catheters can often be removed with continuous, gentle traction, using the technique described by Gladman et al. 4 However, catheter breakage can occur, resulting in the need for surgical removal of catheter fragments, 3 or retrieval during cardiac catheterization. 5 It has even been suggested that M. furfur can contribute to catheter fragility and breakage. 3 Although, thrombolytics have been used in neonates and children to treat both occluded catheters and vascular thromboses, 15 -18 we are unaware of reports of their use in the treatment of catheters that have become adherent to the vessel wall. Given that the only other option may be cardiac catheterization or extensive surgery, 5 a trial of thrombolytics is probably warranted for the patient in whom the catheter cannot be removed with gentle traction to prevent catheter breakage. In one case the infant was too small for cardiac catheterization and too unstable for surgery.
Because both urokinase and r-TPA facilitate lysis of blood clots, there is a risk of both minor and major hemorrhagic complications. In our second case, a chest tube had been placed shortly before Nguyen et al.
Therapy for Adherent Central Venous Catheters beginning r-TPA therapy, and we saw no bleeding from the insertion site when r-TPA was begun. Before beginning thrombolytic therapy in our two cases, we performed cranial ultrasounds to rule out recent intracranial hemorrhage, and checked coagulation studies to rule out unanticipated coagulopathy. Until 1999, urokinase was the thrombolytic agent most commonly used to resolve thrombotic occlusion of central venous catheters. However, in January of 1999 the Food and Drug Administration (FDA) identified problems with the manufacture of urokinase, 19 and issued a list of alternative thrombolytic products including recombinant tissue plasminogen activator (r-TPA). Thus, r-TPA was used in our second case, and is the current agent of choice for resolving thrombotic occlusions of central venous access devices.
We suggest that in cases of adhesion of silicone catheters due to M. furfur or other microorganisms, a trial of thrombolytic therapy may be warranted with careful monitoring and pretreatment screening, even when there is no clear evidence of a large thrombus causing adherence of the catheter.
